Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer

Even though the role of estrogen receptor alpha (ERα) in the modulation of breast cancer cells' behavior is thoroughly studied, the biological functions of its isoform, ERβ, are less elucidated. The suppression of ERβ in the aggressive ERα-negative MDA-MB-231 breast cancer cells resulted in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Matrix biology 2017-12, Vol.64, p.94-111
Hauptverfasser: Piperigkou, Zoi, Franchi, Marco, Götte, Martin, Karamanos, Nikos K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 111
container_issue
container_start_page 94
container_title Matrix biology
container_volume 64
creator Piperigkou, Zoi
Franchi, Marco
Götte, Martin
Karamanos, Nikos K.
description Even though the role of estrogen receptor alpha (ERα) in the modulation of breast cancer cells' behavior is thoroughly studied, the biological functions of its isoform, ERβ, are less elucidated. The suppression of ERβ in the aggressive ERα-negative MDA-MB-231 breast cancer cells resulted in the inhibition of epithelial to mesenchymal transition (EMT) and major changes in the basic functional properties and expression levels of certain matrix components of breast cancer cells. This arrest in metastatic potential of breast cancer cells suggests the contribution of ERβ in the induction of a more aggressive phenotype in MDA-MB-231 breast cancer cells. The epigenetic alterations are responsible for the ability of the tumor cells to metastasize. Here, we report for the first time that the suppression of ERβ in MDA-MB-231 breast cancer cells leads to significant changes in the expression profiles of specific microRNAs, including miR-10b, miR-200b and miR-145. Growth of MCF-7 and MDA-MB-231 cells in estrogen-free medium has a diverse impact on miRNA expression and the behavior of these cells, suggesting the specific effect of estradiol on the miRNA expression profile depending on the ER status of breast cancer cells. Enhanced miR-10b expression or silencing of miR-145 clearly revealed that these microRNAs can regulate the functional properties, EMT program and the expression of major matrix components known to be implicated in breast cancer aggressiveness. Our data revealed that miR-10b is strongly implicated in the regulation of functional properties, EMT program and Erk1/2 signaling in shERβ MDA-MB-231 cells, thus affecting the extracellular matrix (ECM) composition, including syndecan-1, proteolytic behavior, especially MMP2, MMP7 and MMP9 expression and subsequently the aggressiveness of these cells. Accordingly, the inhibition of miR-145 expression significantly increased the aggressiveness of shERβ MDA-MB-231 cells and induced EMT. Moreover, miR-145 inhibition resulted in important changes in the gene and protein levels of ECM mediators, such as HER2 and several MMPs, whereas it significantly increased the phosphorylated levels of Erk1/2 kinases in these cells, suggesting the crucial role of miR-145 in this signaling pathway. These novel results suggest that the alterations in cell behavior and in ECM composition caused by the suppression of ERβ in MDA-MB-231 cells are closely related to certain epigenetic miRNA-induced alterations. Targeting the ERβ-regulat
doi_str_mv 10.1016/j.matbio.2017.08.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1928509994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0945053X17301853</els_id><sourcerecordid>1928509994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-dcd69ca8548d8c2c2a31a41b34ff3a1aa43ee56f5376d156475094c0e1aaa363</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVoSTYf_6AEQS-92J2RZEu-BEpI00KgUELpTcjyuGhZWxvJW8i_rxanOfTQk4TmmRm9D2PvEGoEbD9u68ktfYi1ANQ1mBpAnLANNm1XoQHxhm2gU00Fjfx5xs5z3gKAUtqcsjNhdKc1ig37cZeXFH_RzBN52i8x8Z4Wx13mtA_lnZbg-URDcMdaHPkUvlcIPXfzsN5Vw8PMJzdNLj1z72ZP6ZK9Hd0u09XLecEeP9893n6pHr7df7399FB5JdulGvzQdt6ZRpnBeOGFk-gU9lKNo3TonJJETTs2UrdDSaZ0UzJ5oFJyspUX7MM6dp_i04HyYqeQPe12bqZ4yBY7YUpH16mCvv8H3cZDmsvnrEAEITSiLpRaKZ9izolGu0_hmMsi2KN2u7WrdnvUbsHYor20Xb8MP_TF1WvTX88FuFkBKjJ-B0o2-0DF1BCK98UOMfx_wx9275NY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2110227117</pqid></control><display><type>article</type><title>Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Piperigkou, Zoi ; Franchi, Marco ; Götte, Martin ; Karamanos, Nikos K.</creator><creatorcontrib>Piperigkou, Zoi ; Franchi, Marco ; Götte, Martin ; Karamanos, Nikos K.</creatorcontrib><description>Even though the role of estrogen receptor alpha (ERα) in the modulation of breast cancer cells' behavior is thoroughly studied, the biological functions of its isoform, ERβ, are less elucidated. The suppression of ERβ in the aggressive ERα-negative MDA-MB-231 breast cancer cells resulted in the inhibition of epithelial to mesenchymal transition (EMT) and major changes in the basic functional properties and expression levels of certain matrix components of breast cancer cells. This arrest in metastatic potential of breast cancer cells suggests the contribution of ERβ in the induction of a more aggressive phenotype in MDA-MB-231 breast cancer cells. The epigenetic alterations are responsible for the ability of the tumor cells to metastasize. Here, we report for the first time that the suppression of ERβ in MDA-MB-231 breast cancer cells leads to significant changes in the expression profiles of specific microRNAs, including miR-10b, miR-200b and miR-145. Growth of MCF-7 and MDA-MB-231 cells in estrogen-free medium has a diverse impact on miRNA expression and the behavior of these cells, suggesting the specific effect of estradiol on the miRNA expression profile depending on the ER status of breast cancer cells. Enhanced miR-10b expression or silencing of miR-145 clearly revealed that these microRNAs can regulate the functional properties, EMT program and the expression of major matrix components known to be implicated in breast cancer aggressiveness. Our data revealed that miR-10b is strongly implicated in the regulation of functional properties, EMT program and Erk1/2 signaling in shERβ MDA-MB-231 cells, thus affecting the extracellular matrix (ECM) composition, including syndecan-1, proteolytic behavior, especially MMP2, MMP7 and MMP9 expression and subsequently the aggressiveness of these cells. Accordingly, the inhibition of miR-145 expression significantly increased the aggressiveness of shERβ MDA-MB-231 cells and induced EMT. Moreover, miR-145 inhibition resulted in important changes in the gene and protein levels of ECM mediators, such as HER2 and several MMPs, whereas it significantly increased the phosphorylated levels of Erk1/2 kinases in these cells, suggesting the crucial role of miR-145 in this signaling pathway. These novel results suggest that the alterations in cell behavior and in ECM composition caused by the suppression of ERβ in MDA-MB-231 cells are closely related to certain epigenetic miRNA-induced alterations. Targeting the ERβ-regulated miR-10b and miR-145 is a promising tool for diagnosis and pharmaceutical targeting in breast cancer. •MicroRNA expression profile depends on the ER status of breast cancer cells.•Suppression of ERβ in MDA-MB-231 cells leads to significant changes in the expression profiles of specific microRNAs.•miR-10b over expression and miR-145 silencing revealed that these microRNAs regulate the behavior of breast cancer cells.•Targeting the ERβ-regulated miR-10b and miR-145 is a promising tool for novel pharmaceutical approaches in breast cancer.</description><identifier>ISSN: 0945-053X</identifier><identifier>EISSN: 1569-1802</identifier><identifier>DOI: 10.1016/j.matbio.2017.08.002</identifier><identifier>PMID: 28797712</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>17β-Estradiol ; Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Cell Line, Tumor ; Cell Movement - drug effects ; Cell Proliferation - drug effects ; Cellular biology ; Epigenesis, Genetic ; Epigenetics ; Epithelial-Mesenchymal Transition - drug effects ; Epithelial-to-mesenchymal transition ; ErbB-2 protein ; Estradiol - pharmacology ; Estrogen receptor beta ; Estrogen Receptor beta - antagonists &amp; inhibitors ; Estrogen Receptor beta - metabolism ; Estrogen receptors ; Estrogens ; Extracellular matrix ; Extracellular Matrix Proteins - genetics ; Extracellular Matrix Proteins - metabolism ; Extracellular signal-regulated kinase ; Female ; Gelatinase A ; Gelatinase B ; Gene Expression Regulation, Neoplastic - drug effects ; Humans ; MAP Kinase Signaling System - drug effects ; Matrilysin ; MCF-7 Cells ; Mesenchyme ; Metastases ; MicroRNA ; MicroRNAs - genetics ; miRNA ; Neoplasm Metastasis ; Phenotypes ; Proteolysis ; Signal transduction ; Syndecan ; Tumor cells</subject><ispartof>Matrix biology, 2017-12, Vol.64, p.94-111</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Dec 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-dcd69ca8548d8c2c2a31a41b34ff3a1aa43ee56f5376d156475094c0e1aaa363</citedby><cites>FETCH-LOGICAL-c436t-dcd69ca8548d8c2c2a31a41b34ff3a1aa43ee56f5376d156475094c0e1aaa363</cites><orcidid>0000-0003-4133-3031</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.matbio.2017.08.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28797712$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Piperigkou, Zoi</creatorcontrib><creatorcontrib>Franchi, Marco</creatorcontrib><creatorcontrib>Götte, Martin</creatorcontrib><creatorcontrib>Karamanos, Nikos K.</creatorcontrib><title>Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer</title><title>Matrix biology</title><addtitle>Matrix Biol</addtitle><description>Even though the role of estrogen receptor alpha (ERα) in the modulation of breast cancer cells' behavior is thoroughly studied, the biological functions of its isoform, ERβ, are less elucidated. The suppression of ERβ in the aggressive ERα-negative MDA-MB-231 breast cancer cells resulted in the inhibition of epithelial to mesenchymal transition (EMT) and major changes in the basic functional properties and expression levels of certain matrix components of breast cancer cells. This arrest in metastatic potential of breast cancer cells suggests the contribution of ERβ in the induction of a more aggressive phenotype in MDA-MB-231 breast cancer cells. The epigenetic alterations are responsible for the ability of the tumor cells to metastasize. Here, we report for the first time that the suppression of ERβ in MDA-MB-231 breast cancer cells leads to significant changes in the expression profiles of specific microRNAs, including miR-10b, miR-200b and miR-145. Growth of MCF-7 and MDA-MB-231 cells in estrogen-free medium has a diverse impact on miRNA expression and the behavior of these cells, suggesting the specific effect of estradiol on the miRNA expression profile depending on the ER status of breast cancer cells. Enhanced miR-10b expression or silencing of miR-145 clearly revealed that these microRNAs can regulate the functional properties, EMT program and the expression of major matrix components known to be implicated in breast cancer aggressiveness. Our data revealed that miR-10b is strongly implicated in the regulation of functional properties, EMT program and Erk1/2 signaling in shERβ MDA-MB-231 cells, thus affecting the extracellular matrix (ECM) composition, including syndecan-1, proteolytic behavior, especially MMP2, MMP7 and MMP9 expression and subsequently the aggressiveness of these cells. Accordingly, the inhibition of miR-145 expression significantly increased the aggressiveness of shERβ MDA-MB-231 cells and induced EMT. Moreover, miR-145 inhibition resulted in important changes in the gene and protein levels of ECM mediators, such as HER2 and several MMPs, whereas it significantly increased the phosphorylated levels of Erk1/2 kinases in these cells, suggesting the crucial role of miR-145 in this signaling pathway. These novel results suggest that the alterations in cell behavior and in ECM composition caused by the suppression of ERβ in MDA-MB-231 cells are closely related to certain epigenetic miRNA-induced alterations. Targeting the ERβ-regulated miR-10b and miR-145 is a promising tool for diagnosis and pharmaceutical targeting in breast cancer. •MicroRNA expression profile depends on the ER status of breast cancer cells.•Suppression of ERβ in MDA-MB-231 cells leads to significant changes in the expression profiles of specific microRNAs.•miR-10b over expression and miR-145 silencing revealed that these microRNAs regulate the behavior of breast cancer cells.•Targeting the ERβ-regulated miR-10b and miR-145 is a promising tool for novel pharmaceutical approaches in breast cancer.</description><subject>17β-Estradiol</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Cell Movement - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>Cellular biology</subject><subject>Epigenesis, Genetic</subject><subject>Epigenetics</subject><subject>Epithelial-Mesenchymal Transition - drug effects</subject><subject>Epithelial-to-mesenchymal transition</subject><subject>ErbB-2 protein</subject><subject>Estradiol - pharmacology</subject><subject>Estrogen receptor beta</subject><subject>Estrogen Receptor beta - antagonists &amp; inhibitors</subject><subject>Estrogen Receptor beta - metabolism</subject><subject>Estrogen receptors</subject><subject>Estrogens</subject><subject>Extracellular matrix</subject><subject>Extracellular Matrix Proteins - genetics</subject><subject>Extracellular Matrix Proteins - metabolism</subject><subject>Extracellular signal-regulated kinase</subject><subject>Female</subject><subject>Gelatinase A</subject><subject>Gelatinase B</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Humans</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Matrilysin</subject><subject>MCF-7 Cells</subject><subject>Mesenchyme</subject><subject>Metastases</subject><subject>MicroRNA</subject><subject>MicroRNAs - genetics</subject><subject>miRNA</subject><subject>Neoplasm Metastasis</subject><subject>Phenotypes</subject><subject>Proteolysis</subject><subject>Signal transduction</subject><subject>Syndecan</subject><subject>Tumor cells</subject><issn>0945-053X</issn><issn>1569-1802</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVoSTYf_6AEQS-92J2RZEu-BEpI00KgUELpTcjyuGhZWxvJW8i_rxanOfTQk4TmmRm9D2PvEGoEbD9u68ktfYi1ANQ1mBpAnLANNm1XoQHxhm2gU00Fjfx5xs5z3gKAUtqcsjNhdKc1ig37cZeXFH_RzBN52i8x8Z4Wx13mtA_lnZbg-URDcMdaHPkUvlcIPXfzsN5Vw8PMJzdNLj1z72ZP6ZK9Hd0u09XLecEeP9893n6pHr7df7399FB5JdulGvzQdt6ZRpnBeOGFk-gU9lKNo3TonJJETTs2UrdDSaZ0UzJ5oFJyspUX7MM6dp_i04HyYqeQPe12bqZ4yBY7YUpH16mCvv8H3cZDmsvnrEAEITSiLpRaKZ9izolGu0_hmMsi2KN2u7WrdnvUbsHYor20Xb8MP_TF1WvTX88FuFkBKjJ-B0o2-0DF1BCK98UOMfx_wx9275NY</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Piperigkou, Zoi</creator><creator>Franchi, Marco</creator><creator>Götte, Martin</creator><creator>Karamanos, Nikos K.</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4133-3031</orcidid></search><sort><creationdate>201712</creationdate><title>Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer</title><author>Piperigkou, Zoi ; Franchi, Marco ; Götte, Martin ; Karamanos, Nikos K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-dcd69ca8548d8c2c2a31a41b34ff3a1aa43ee56f5376d156475094c0e1aaa363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>17β-Estradiol</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Cell Movement - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>Cellular biology</topic><topic>Epigenesis, Genetic</topic><topic>Epigenetics</topic><topic>Epithelial-Mesenchymal Transition - drug effects</topic><topic>Epithelial-to-mesenchymal transition</topic><topic>ErbB-2 protein</topic><topic>Estradiol - pharmacology</topic><topic>Estrogen receptor beta</topic><topic>Estrogen Receptor beta - antagonists &amp; inhibitors</topic><topic>Estrogen Receptor beta - metabolism</topic><topic>Estrogen receptors</topic><topic>Estrogens</topic><topic>Extracellular matrix</topic><topic>Extracellular Matrix Proteins - genetics</topic><topic>Extracellular Matrix Proteins - metabolism</topic><topic>Extracellular signal-regulated kinase</topic><topic>Female</topic><topic>Gelatinase A</topic><topic>Gelatinase B</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Humans</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Matrilysin</topic><topic>MCF-7 Cells</topic><topic>Mesenchyme</topic><topic>Metastases</topic><topic>MicroRNA</topic><topic>MicroRNAs - genetics</topic><topic>miRNA</topic><topic>Neoplasm Metastasis</topic><topic>Phenotypes</topic><topic>Proteolysis</topic><topic>Signal transduction</topic><topic>Syndecan</topic><topic>Tumor cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piperigkou, Zoi</creatorcontrib><creatorcontrib>Franchi, Marco</creatorcontrib><creatorcontrib>Götte, Martin</creatorcontrib><creatorcontrib>Karamanos, Nikos K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Matrix biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piperigkou, Zoi</au><au>Franchi, Marco</au><au>Götte, Martin</au><au>Karamanos, Nikos K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer</atitle><jtitle>Matrix biology</jtitle><addtitle>Matrix Biol</addtitle><date>2017-12</date><risdate>2017</risdate><volume>64</volume><spage>94</spage><epage>111</epage><pages>94-111</pages><issn>0945-053X</issn><eissn>1569-1802</eissn><abstract>Even though the role of estrogen receptor alpha (ERα) in the modulation of breast cancer cells' behavior is thoroughly studied, the biological functions of its isoform, ERβ, are less elucidated. The suppression of ERβ in the aggressive ERα-negative MDA-MB-231 breast cancer cells resulted in the inhibition of epithelial to mesenchymal transition (EMT) and major changes in the basic functional properties and expression levels of certain matrix components of breast cancer cells. This arrest in metastatic potential of breast cancer cells suggests the contribution of ERβ in the induction of a more aggressive phenotype in MDA-MB-231 breast cancer cells. The epigenetic alterations are responsible for the ability of the tumor cells to metastasize. Here, we report for the first time that the suppression of ERβ in MDA-MB-231 breast cancer cells leads to significant changes in the expression profiles of specific microRNAs, including miR-10b, miR-200b and miR-145. Growth of MCF-7 and MDA-MB-231 cells in estrogen-free medium has a diverse impact on miRNA expression and the behavior of these cells, suggesting the specific effect of estradiol on the miRNA expression profile depending on the ER status of breast cancer cells. Enhanced miR-10b expression or silencing of miR-145 clearly revealed that these microRNAs can regulate the functional properties, EMT program and the expression of major matrix components known to be implicated in breast cancer aggressiveness. Our data revealed that miR-10b is strongly implicated in the regulation of functional properties, EMT program and Erk1/2 signaling in shERβ MDA-MB-231 cells, thus affecting the extracellular matrix (ECM) composition, including syndecan-1, proteolytic behavior, especially MMP2, MMP7 and MMP9 expression and subsequently the aggressiveness of these cells. Accordingly, the inhibition of miR-145 expression significantly increased the aggressiveness of shERβ MDA-MB-231 cells and induced EMT. Moreover, miR-145 inhibition resulted in important changes in the gene and protein levels of ECM mediators, such as HER2 and several MMPs, whereas it significantly increased the phosphorylated levels of Erk1/2 kinases in these cells, suggesting the crucial role of miR-145 in this signaling pathway. These novel results suggest that the alterations in cell behavior and in ECM composition caused by the suppression of ERβ in MDA-MB-231 cells are closely related to certain epigenetic miRNA-induced alterations. Targeting the ERβ-regulated miR-10b and miR-145 is a promising tool for diagnosis and pharmaceutical targeting in breast cancer. •MicroRNA expression profile depends on the ER status of breast cancer cells.•Suppression of ERβ in MDA-MB-231 cells leads to significant changes in the expression profiles of specific microRNAs.•miR-10b over expression and miR-145 silencing revealed that these microRNAs regulate the behavior of breast cancer cells.•Targeting the ERβ-regulated miR-10b and miR-145 is a promising tool for novel pharmaceutical approaches in breast cancer.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28797712</pmid><doi>10.1016/j.matbio.2017.08.002</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-4133-3031</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0945-053X
ispartof Matrix biology, 2017-12, Vol.64, p.94-111
issn 0945-053X
1569-1802
language eng
recordid cdi_proquest_miscellaneous_1928509994
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects 17β-Estradiol
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Cell Line, Tumor
Cell Movement - drug effects
Cell Proliferation - drug effects
Cellular biology
Epigenesis, Genetic
Epigenetics
Epithelial-Mesenchymal Transition - drug effects
Epithelial-to-mesenchymal transition
ErbB-2 protein
Estradiol - pharmacology
Estrogen receptor beta
Estrogen Receptor beta - antagonists & inhibitors
Estrogen Receptor beta - metabolism
Estrogen receptors
Estrogens
Extracellular matrix
Extracellular Matrix Proteins - genetics
Extracellular Matrix Proteins - metabolism
Extracellular signal-regulated kinase
Female
Gelatinase A
Gelatinase B
Gene Expression Regulation, Neoplastic - drug effects
Humans
MAP Kinase Signaling System - drug effects
Matrilysin
MCF-7 Cells
Mesenchyme
Metastases
MicroRNA
MicroRNAs - genetics
miRNA
Neoplasm Metastasis
Phenotypes
Proteolysis
Signal transduction
Syndecan
Tumor cells
title Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T20%3A32%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estrogen%20receptor%20beta%20as%20epigenetic%20mediator%20of%20miR-10b%20and%20miR-145%20in%20mammary%20cancer&rft.jtitle=Matrix%20biology&rft.au=Piperigkou,%20Zoi&rft.date=2017-12&rft.volume=64&rft.spage=94&rft.epage=111&rft.pages=94-111&rft.issn=0945-053X&rft.eissn=1569-1802&rft_id=info:doi/10.1016/j.matbio.2017.08.002&rft_dat=%3Cproquest_cross%3E1928509994%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2110227117&rft_id=info:pmid/28797712&rft_els_id=S0945053X17301853&rfr_iscdi=true